Gain Therapeutics is trading 5.32% down at $1.33 on October 14, 2026, with no clear company-specific catalyst identified. - The previously announced Maxim Growth Summit participation is not clearly linked to the decline. - Broader risk-off sentiment may be adding pressure after September core CPI rose more than expected, prompting concern about tighter Federal Reserve policy and weighing on growth stocks. Biotechnology shares also weakened in recent sessions, but available reports do not establish a sector decline during today’s session.